OB/GYN Clinical Alert – December 1, 2004
December 1, 2004
View Issues
-
Obstetrical Prognosis after Placental Abruption
In a recent study from Japan, Toivonen and colleagues set out to determine how much more susceptible women experiencing placental abruption were to having a recurrence of this problem in a subsequent pregnancy. They scanned a database which encompassed 14,326 deliveries during a one-year period at a busy university hospital. -
Venous Thrombosis and Type of Treatment
Smith and colleagues performed a case-control study of venous thrombosis and hormone users in postmenopausal women registered in a large health maintenance organization (the Group Health Cooperative) in the state of Washington. -
Usefulness of History, Physical, and Laboratory in Evaluating Vaginal Complaints
In working up vaginitis symptoms, useful signs are inflammation and odor, information concerning odor and itching are useful symptoms, and office microscopy is the most accurate laboratory test. -
Aromatase Inhibitor for Severe Endometriosis
Two premenopausal patients with resis tant endometriosis were successfully treated with a combination of the aromatase inhibitor anastrozole, Prometrium, calcitrol, and rofecoxib. Both patients had been diagnosed with endometriosis via laparoscopy, and had undergone GnRH suppression. -
Timing Isn’t Everything, Right?
Nearly 70% of patients achieving a CR after primary therapy eventually recurred. Most recurrences occurred more than 6 months from completion of primary chemotherapy, and the use of second line agents at the time of recurrence was effective. -
Postmenopausal Hormone Therapy and Venous Thrombosis
Results from the estrogen-progestin arm of the Womens Health Initiative confirm (after central adjudication of the diagnoses) an increase in venous thrombosis associated with a standard dose of postmenopausal hormone therapy. -
Binders
-
Readers are Invited. . .
-
Pharmacology Watch: ACE Inhibitors and Receptor Blockers: Which is Inferior?
The Infection Risk of Acid-Suppressing Drugs; Is Rosuvastatin As Safe As Other Statins?; Which Estrogen Preparation is the Safest?; FDA Actions. -
Clinical Briefs in Primary Care supplement